These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29382011)

  • 1. Biodegradable polymer drug-eluting stents versus first-generation durable polymer drug-eluting stents: A systematic review and meta-analysis of 12 randomized controlled trials.
    Bundhun PK; Pursun M; Huang F
    Medicine (Baltimore); 2017 Nov; 96(47):e8878. PubMed ID: 29382011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse cardiovascular events associated with biodegradable polymer drug-eluting stents and durable polymer everolimus-eluting stents: A systematic review and meta-analysis of 10 randomized controlled trials.
    Bundhun PK; Janoo G; Yanamala CM; Huang F
    Medicine (Baltimore); 2017 Jul; 96(28):e7510. PubMed ID: 28700502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials.
    Kobayashi T; Sotomi Y; Suzuki S; Suwannasom P; Nakatani S; Morino Y; Ako J; Kozuma K; Hirayama A; Sakata Y; Higuchi Y
    Cardiovasc Interv Ther; 2020 Jul; 35(3):250-258. PubMed ID: 31422529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents.
    El-Hayek G; Bangalore S; Casso Dominguez A; Devireddy C; Jaber W; Kumar G; Mavromatis K; Tamis-Holland J; Samady H
    JACC Cardiovasc Interv; 2017 Mar; 10(5):462-473. PubMed ID: 28279314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials.
    Bavishi C; Chugh Y; Kimura T; Natsuaki M; Kaiser C; Gordon P; Aronow HD; Abbott JD
    Eur Heart J Qual Care Clin Outcomes; 2020 Jan; 6(1):81-88. PubMed ID: 31228186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials.
    Lou Y; Yu Y; Xi Z; Gao Y; Liu W; Nie X
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):557-566. PubMed ID: 31773343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome: a meta-analysis.
    Yuan H; Wu Z; Lu T; Wei T; Zeng Y; Liu Y; Huang C
    BMJ Open; 2022 Jun; 12(6):e058075. PubMed ID: 35676012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Clinical Outcomes of Biodegradable-Polymer Drug-Eluting Stents Versus Second-Generation Durable-Polymer Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction.
    Sim HW; Thong EH; Djohan AH; Chen JZ; Ser JS; Loh PH; Lee CH; Chan MY; Low AF; Tay EL; Chan KH; Tan HC; Loh JP
    Cardiovasc Revasc Med; 2022 Feb; 35():98-103. PubMed ID: 33893053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of degradable vs. permanent polymer drug-eluting stents: a meta-analysis of 18,395 patients from randomized trials.
    Wang Y; Liu S; Luo Y; Wang F; Liu H; Li L; Zhao X; Huang L
    Int J Cardiol; 2014 Apr; 173(1):100-9. PubMed ID: 24613365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients.
    Lupi A; Rognoni A; Secco GG; Lazzero M; Nardi F; Fattori R; Bongo AS; Agostoni P; Sheiban I
    Eur J Prev Cardiol; 2014 Apr; 21(4):411-24. PubMed ID: 23152364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.
    de Waha A; Stefanini GG; King LA; Byrne RA; Serruys PW; Kufner S; Meier B; Jüni P; Kastrati A; Windecker S
    Int J Cardiol; 2013 Oct; 168(6):5162-6. PubMed ID: 23993323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.
    Lupi A; Gabrio Secco G; Rognoni A; Lazzero M; Fattori R; Sheiban I; Sante Bongo A; Bolognese L; Agostoni P; Porto I
    Catheter Cardiovasc Interv; 2014 May; 83(6):E193-206. PubMed ID: 24478247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year outcomes of biodegradable versus second-generation durable polymer drug-eluting stents used in complex percutaneous coronary intervention.
    Xu N; Jiang L; Yao Y; Xu J; Liu R; Wang H; Song Y; Gao L; Gao Z; Zhao X; Xu B; Han Y; Yuan J
    Chin Med J (Engl); 2023 Feb; 136(3):322-330. PubMed ID: 36848178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials.
    de Waha A; King LA; Stefanini GG; Byrne RA; Serruys PW; Meier B; Jüni P; Kastrati A; Windecker S
    EuroIntervention; 2015 Apr; 10(12):1425-31. PubMed ID: 24602961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the biodegradable polymer everolimus-eluting stent with contemporary drug-eluting stents: A systematic review and meta-analysis.
    Picard F; Pighi M; de Hemptinne Q; Airaksinen J; Vinco G; de Pommereau A; Biancari F; Varenne O
    Int J Cardiol; 2019 Mar; 278():51-56. PubMed ID: 30503189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials.
    Zhu P; Zhou X; Zhang C; Li H; Zhang Z; Song Z
    BMC Cardiovasc Disord; 2018 Aug; 18(1):170. PubMed ID: 30111289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodegradable-Polymer Versus Polymer-Free Drug-Eluting Stents for the Treatment of Coronary Artery Disease.
    Nogic J; Thein P; Mirzaee S; Comella A; Soon K; Cameron JD; West NEJ; Brown AJ
    Cardiovasc Revasc Med; 2019 Oct; 20(10):865-870. PubMed ID: 30578169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of biodegradable polymer sirolimus-eluting stents versus durable polymer drug-eluting stents: A meta-analysis of randomized trials.
    Yang Y; Lei J; Huang W; Lei H
    Int J Cardiol; 2016 Nov; 222():486-493. PubMed ID: 27505339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes of Biodegradable Versus Second-Generation Durable Polymer Drug-Eluting Stent Implantations for Myocardial Infarction.
    Choe JC; Cha KS; Lee JG; Kim J; Shin JY; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    JACC Cardiovasc Interv; 2020 Jan; 13(1):97-111. PubMed ID: 31918948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.